Spots Global Cancer Trial Database for Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Official Title: Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Study ID: NCT01880749
Interventions
Study Description
Brief Summary: The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry. This is a "phase 0" PK (pharmacokinetic) and PD (pharmacodynamic) study of RAD001 in patients with Neurofibromatosis Type 2-related and sporadic VS and meningiomas. Enrolled patients will take RAD001 prior to a scheduled VS or meningioma surgery, and blood and tissue samples will be obtained for further analysis.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
New York University School of Medicine, New York, New York, United States
Contact Details
Name: Theodore Nicolaides, MD
Affiliation: NYU Langone Health
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
